BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
NOVOLOG MIX 70/30 (insulin aspart) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2001.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLOG MIX 70/30 is a premixed insulin aspart combination (70% insulin aspart protamine suspension, 30% insulin aspart) administered subcutaneously for diabetes management. It combines rapid-acting and intermediate-acting insulin to provide coverage for meals and basal glucose control. This product is indicated for patients with type 1 and type 2 diabetes requiring insulin therapy.
LOE Approaching
Product faces significant loss-of-exclusivity pressure with a mature, competitive insulin market; commercial teams should anticipate portfolio rationalization and shift focus to next-generation formulations.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Started Jul 2023
414 enrolled
Diabetes
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Started Nov 2021
679 enrolled
Diabetes Mellitus, Type 2
A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
Started Apr 2021
200 enrolled
Diabetes Mellitus, Type 2
Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart
Started Dec 2020
18 enrolled
Diabetes Mellitus, Type 1
Worked on NOVOLOG MIX 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.